Torrent Pharmaceuticals Resultados de beneficios anteriores
Pasado controles de criterios 6/6
Torrent Pharmaceuticals ha aumentado sus beneficios a una tasa media anual de 14.2%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 17% anual. Los ingresos han ido creciendo a una tasa media de 6.6% al año. La rentabilidad financiera de Torrent Pharmaceuticals es de 24.2%, y sus márgenes netos son de 15.4%.
Información clave
14.2%
Tasa de crecimiento de los beneficios
14.2%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 17.5% |
| Tasa de crecimiento de los ingresos | 6.6% |
| Rentabilidad financiera | 24.2% |
| Margen neto | 15.4% |
| Próxima actualización de resultados | 23 Jul 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) P/E Is On The Mark
Apr 16
Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?
Mar 03Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹22.00
Feb 05Investors Interested In Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Earnings
Jan 07Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Rather Sparingly
Nov 14Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jun 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Mar 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jul 25Torrent Pharmaceuticals' (NSE:TORNTPHARM) Soft Earnings Don't Show The Whole Picture
Jun 02Estimating The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
May 25A Look At The Intrinsic Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
Feb 18Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹25.00
Jan 27Here's Why Torrent Pharmaceuticals (NSE:TORNTPHARM) Can Manage Its Debt Responsibly
Jan 04Here's Why I Think Torrent Pharmaceuticals (NSE:TORNTPHARM) Is An Interesting Stock
Dec 14A Look At The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
Nov 07Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Sep 30Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Deserve A Spot On Your Watchlist?
Sep 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jul 02I Ran A Stock Scan For Earnings Growth And Torrent Pharmaceuticals (NSE:TORNTPHARM) Passed With Ease
Jun 01Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Shares Could Be 30% Above Their Intrinsic Value Estimate
May 14Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?
Mar 23The Torrent Pharmaceuticals (NSE:TORNTPHARM) Share Price Has Gained 84% And Shareholders Are Hoping For More
Mar 02Is It Smart To Buy Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Before It Goes Ex-Dividend?
Feb 10Do Torrent Pharmaceuticals's (NSE:TORNTPHARM) Earnings Warrant Your Attention?
Jan 19Should You Be Impressed By Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) ROE?
Dec 29Is Torrent Pharmaceuticals (NSE:TORNTPHARM) Using Too Much Debt?
Dec 08
Investors Who Bought Torrent Pharmaceuticals (NSE:TORNTPHARM) Shares Three Years Ago Are Now Up 118%
Nov 16Desglose de ingresos y gastos
Cómo gana y gasta dinero Torrent Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Mar 24 | 107,278 | 16,564 | 20,166 | 0 |
| 31 Dec 23 | 104,742 | 14,942 | 19,662 | 0 |
| 30 Sep 23 | 102,332 | 13,432 | 18,932 | 0 |
| 30 Jun 23 | 98,642 | 12,692 | 17,842 | 0 |
| 31 Mar 23 | 96,202 | 12,452 | 17,052 | 0 |
| 31 Dec 22 | 92,580 | 8,312 | 16,233 | 0 |
| 30 Sep 22 | 88,750 | 7,972 | 15,883 | 0 |
| 30 Jun 22 | 87,210 | 8,012 | 15,833 | 0 |
| 31 Mar 22 | 85,080 | 7,772 | 15,483 | 0 |
| 31 Dec 21 | 83,158 | 12,189 | 15,227 | 0 |
| 30 Sep 21 | 82,028 | 12,669 | 14,977 | 0 |
| 30 Jun 21 | 80,828 | 12,609 | 14,717 | 0 |
| 31 Mar 21 | 80,046 | 12,519 | 14,597 | 0 |
| 31 Dec 20 | 80,143 | 12,417 | 14,350 | 0 |
| 30 Sep 20 | 79,853 | 11,957 | 14,260 | 0 |
| 30 Jun 20 | 79,733 | 11,297 | 14,210 | 0 |
| 31 Mar 20 | 79,393 | 10,247 | 14,421 | 0 |
| 31 Dec 19 | 78,488 | 5,593 | 14,398 | 0 |
| 30 Sep 19 | 79,338 | 5,543 | 14,538 | 0 |
| 30 Jun 19 | 78,228 | 4,893 | 14,388 | 0 |
| 31 Mar 19 | 76,728 | 4,363 | 14,038 | 0 |
| 31 Dec 18 | 75,141 | 8,161 | 13,743 | 0 |
| 30 Sep 18 | 69,891 | 6,281 | 12,783 | 0 |
| 30 Jun 18 | 65,121 | 6,531 | 12,183 | 0 |
| 31 Mar 18 | 59,498 | 6,781 | 11,353 | 0 |
| 31 Dec 17 | 56,727 | 6,556 | 10,674 | 0 |
| 30 Sep 17 | 56,387 | 8,266 | 10,284 | 0 |
| 30 Jun 17 | 56,387 | 8,296 | 10,044 | 0 |
| 31 Mar 17 | 58,157 | 9,336 | 9,934 | 0 |
| 31 Dec 16 | 59,154 | 10,014 | 10,233 | 0 |
| 30 Sep 16 | 60,144 | 10,624 | 9,913 | 0 |
| 30 Jun 16 | 62,744 | 13,644 | 9,393 | 0 |
| 31 Mar 16 | 66,669 | 17,332 | 8,424 | 0 |
| 31 Dec 15 | 63,315 | 16,299 | 18,653 | 0 |
| 30 Sep 15 | 59,605 | 13,139 | 18,583 | 0 |
| 30 Jun 15 | 54,865 | 9,439 | 18,723 | 0 |
| 31 Mar 15 | 46,535 | 7,509 | 8,772 | 0 |
| 31 Dec 14 | 47,247 | 8,649 | 16,510 | 0 |
| 30 Sep 14 | 45,717 | 8,559 | 16,310 | 0 |
| 30 Jun 14 | 43,267 | 7,709 | 15,890 | 0 |
| 31 Mar 14 | 41,847 | 6,639 | 15,770 | 0 |
| 31 Dec 13 | 38,291 | 5,308 | 13,901 | 0 |
| 30 Sep 13 | 36,111 | 4,858 | 13,631 | 0 |
Ingresos de calidad: TORNTPHARM tiene ganancias de alta calidad.
Margen de beneficios creciente: Los actuales márgenes de beneficio (14.3%) de TORNTPHARM son superiores a los del año pasado (9%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: Los beneficios de TORNTPHARM han crecido un 12.4% al año en los últimos 5 años.
Acelerando crecimiento: El crecimiento de los beneficios de TORNTPHARM en el último año (33%) supera su media de 5 años (14.2% al año).
Beneficios vs. Industria: El crecimiento de los beneficios de TORNTPHARM en el último año (33%) superó al de la industria Pharmaceuticals 18.4%.
Rentabilidad financiera
Alta ROE: La rentabilidad financiera (24.2%) de TORNTPHARM se considera alta.